Immunogenicity and Safety Study of Two Different Formulations of GlaxoSmithKline (GSK) Biologicals' Oral Live Attenuated Human Rotavirus (HRV) Vaccine, Rotarix in Healthy Infants
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 15 Nov 2017
At a glance
- Drugs Rotavirus vaccine (Primary)
- Indications Rotavirus infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline
- 09 Nov 2017 Planned number of patients changed from 308 to 450.
- 23 Oct 2017 Planned End Date changed from 27 May 2018 to 18 May 2019.
- 23 Oct 2017 Planned primary completion date changed from 27 May 2018 to 25 Feb 2019.